Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials.

Blauvelt, A

Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials. [electronic resource] - The British journal of dermatology 09 2018 - 615-622 p. digital

Publication Type: Journal Article

1365-2133

10.1111/bjd.16724 doi


Adult
Antibodies, Monoclonal--administration & dosage
Antibodies, Monoclonal, Humanized
Candida albicans--immunology
Candidiasis--epidemiology
Cardiovascular Diseases--chemically induced
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Dose-Response Relationship, Drug
Etanercept--administration & dosage
Female
Humans
Immunosuppressive Agents--administration & dosage
Inflammatory Bowel Diseases--epidemiology
Interleukin-23 Subunit p19--antagonists & inhibitors
Male
Middle Aged
Placebos--administration & dosage
Psoriasis--diagnosis
Randomized Controlled Trials as Topic
Severity of Illness Index
Time Factors
Treatment Outcome